Table 1.
Characteristics of the included CF patients (n = 114).
| Variable | N (%) | |
|---|---|---|
| Sex | Female | 61 (52.6%) |
| Male | 53 (47.4%) | |
| Genotype | F508del/F508del | 48 (42.1%) |
| F508del/other | 53 (46.5%) | |
| G551D/other | 15 (13.0%) | |
| Other/other | 13 (10.7%) | |
| Age (yrs.) | 0–5 | 17 (14.9%) |
| 6–11 | 25 (21.9%) | |
| 12–17 | 14 (12.3%) | |
| ≥18 | 58 (50.9%) | |
| Therapy | Antibiotic therapy in the previous 3 months | 84 (73.7%) |
| Pancreatic enzymes intake | 107 (93.9%) | |
| Proton pump inhibitors (PPI) | 30 (36.3%) | |
| Comorbidities | Exocrine pancreatic insufficiency (EPI) | 106 (93.0%) |
| Meconium ileus (MI) | 9 (7.9%) | |
| Distal intestinal obstruction syndrome (DIOS) | 11 (9.6%) | |
| Rectal prolapse | 13 (11.4%) | |
| CF liver disease (CFLD) | 21 (18.4%) | |
| Small bowel resection | 9 (7.9%) | |
| Serum | Elevated† ALT | 60 (52.6%) |
| Elevated† AST | 25 (21.9%) | |
| Elevated† γ-GT | 12 (10.5%) | |
| Elevated† AP | 48 (42.1%) | |
| Platelet counts reduced | 5 (4.4%) |
†Elevated in regard to age and gender-related reference.
ALT: alanine aminotransferase; AST: aspartate aminotransferase; γ-GT: γ-glutamyl transpeptidase;
and AP: alkaline phosphatase.